Objectives: We conducted a systematic review of the literature on the effectiveness and complications of programmable intrathecal opioid and ziconotide drug delivery systems (IDDS) for patients with chronic noncancer pain.
I ntrathecal opioid therapy via implantable drug delivery systems (IDDS) has been an option for the treatment of chronic pain since the early 1980s. The potential advantages of IDDS over other modes of opioid delivery include lower doses required for pain relief and hence less severe side effects. The first IDDS pumps delivered medication at a fixed, continuous rate. With fixed-rate pumps, dosing changes can only be made by refilling the pump with a different concentration of the medication. 1, 2 In 1991, an externally programmable IDDS pump powered by batteries [SynchroMed, Medtronic, Inc (Minneapolis, MN)] was released in the United States (US). 1 With this pump, the flow rate (and therefore the dose of the medication) is externally programmable, allowing noninvasive changes in medication doses. However, the pump must be removed and replaced when the battery fails. 1 In general, programmable pumps rather than fixed-rate pumps are implanted when dosage changes are likely, as is the case with chronic pain problems. 2 This review was limited to programmable pumps because the vast majority of all intrathecal pumps implanted currently for chronic noncancer pain are programmable.
The programmable system consists of a pump implanted into an abdominal subcutaneous pocket; a catheter that is inserted into the intrathecal space of the spine and tunneled under the skin, connecting to the pump; and an external programmer that controls infusion rate and records medication concentration, volume, and dosage. The pump requires refilling regularly via subcutaneous port injections. Various trial techniques are used to select patients for permanent pump implantation (usually on the basis of Z50% pain relief and ability to tolerate the drug). Until recently, preservative-free morphine sulfate was the only drug approved by the US Food and Drug Administration (FDA) for use in intrathecal pumps for pain treatment. In 2004, the FDA approved the use of ziconotide, a calcium channel blocker, in intrathecal pumps for patients with chronic refractory pain unresponsive to intrathecally delivered morphine. However, off-label use of drugs in intrathecal pumps is common. 3 Given the high costs of chronic noncancer pain 4-6 and of IDDS, 7, 8 there is an urgent need for high-quality data regarding the effectiveness of IDDS in relieving pain and improving function. Conclusive information would be of great interest to patients with chronic pain, clinicians, and payers. IDDS literature reviews have been published, 2, 9, 10 but these are now several years old and they did not focus separately on studies of programmable IDDS for patients with failed back surgery syndrome (FBSS) and other noncancer pain syndromes that are not due to a specific disease.
We therefore conducted a systematic review of the literature on the effectiveness and complications of programmable IDDS with opioid medication or ziconotide for the treatment of chronic noncancer pain. We followed published guidelines for systematic reviews in the field of spinal disorders. 11 We addressed 2 primary questions: (1) What are the effects on pain and functioning, and do they change over time? (2) What are the types and rates of complications?
We also looked for information on changes in IDDS drugs and doses over time and on predictors of patient response to IDDS. A final goal was to summarize the gaps in scientific knowledge of IDDS outcomes and complications, and make recommendations for future studies that could better define the benefits and risks of this technology.
METHODS

Article Selection
With the help of an experienced health sciences librarian, we searched each of the following bibliographic databases from its starting date through October 10, 2005 (the starting date and number of articles identified from each database are specified in parentheses): PubMed including MEDLINE (1950; 460), Science Citation Index Expanded (1965; 346), Cochrane Central Register of Controlled Trials (1950; 32) , EMBASE Drugs and Pharmacology (1980; 296), Current Contents Connect (1998; 167), Global Health (1973; 2), and International Pharmaceutical Abstracts (1970; 17) . We tailored literature search strategies to the controlled vocabulary for each bibliographic database searched (see Appendix). The search strategies did not include terms for health conditions or pain type because of the wide range of indications for IDDS and the broad diagnostic categories involved. Instead, we based the searches on 4 conceptual components: implantable, pump, intrathecal, and opioid (or ziconotide). We checked the search sensitivity by ensuring that almost all articles identified via manual bibliography reviews were identified via one or more of the structured bibliographic database searches. In addition, we asked a representative of Medtronic, Inc, for suggestions of articles to screen for inclusion. Finally, we searched our personal files, journals, and books, and reviewed the bibliographies of screened articles and previous reviews for additional studies.
From these searches, we identified English-language articles relevant to IDDS effectiveness or complications among patients with chronic noncancer pain. Two authors (J.A.T., J.M.S.) independently reviewed each of these articles to determine whether it met the following basic inclusion criteria for both the effectiveness and the complications reviews: (1) English-language journal article (published conference abstracts were excluded);
(2) article addressed pain treatment with opioid or ziconotide delivered intrathecally via programmable pumps; (3) patient diagnoses not limited to spasticity or specific diseases (eg, cancer, sickle cell disease); and (4) article contained original data on pain, functioning, or complications in humans. Articles that did not meet these 4 criteria were not screened further.
Articles that met these basic criteria were reviewed independently by the same 2 authors to determine whether they met the following more detailed inclusion criteria for both the effectiveness and complications reviews: (1) the only pump studied was programmable or data were presented separately for patients with programmable pumps (if it was not clear what type of pump was received by all patients, attempts were made to contact the article authors for this information. In cases where the type of pump remained unknown, the article was excluded.) and (2) the first medication delivered intrathecally to all study participants was an opioid (with or without adjuvant medications) or ziconotide. The exclusion criteria for both the IDDS effectiveness and complications reviews were: (1) more than 10% of the sample were being treated for spasticity or pain associated with a specific disease [eg, cancer, acquired immune deficiency syndrome, sickle cell disease, multiple sclerosis, spinal cord injury] and data on pain, functioning, or complications were not presented separately for patients without these conditions; (2) study focused only on patients who did not respond to the first IDDS drug they were given (unless the study was of ziconotide); and (3) case report.
Two authors (J.A.T., J.M.S.) independently used the American Academy of Neurology (AAN) Quality Standards Subcommittee classification scheme 12 to classify the methodologic strength of each study that met the inclusion criteria listed above. According to this scheme, Class I studies are randomized, controlled trials (RCTs) that meet additional specified methodologic quality criteria; Class II studies include prospective matched group cohort studies that meet specified methodologic quality criteria and RCTs in a representative population that lack one of the specified criteria for Class I RCTs;
Class III studies are all other controlled trials in a representative population with outcomes assessed independently of patient treatment; and Class IV studies include uncontrolled studies, case series, case reports, and expert opinion. For the effectiveness review (but not the complications review), an additional inclusion criterion was study Class I-III or a Class IV study with (1) independent observer-completed or patient-completed standardized measures of pain or functioning obtained both before IDDS implantation (or ziconotide initiation) and at planned, regular follow-ups; (2) data from patient baseline descriptive and outcome measures reported for all study participants who underwent pump implantation (or ziconotide initiation) during the study period; and (3) original data reported on pain or functioning before IDDS implantation (or ziconotide initiation) and for Z75% of implanted patients at a follow-up Z6 months.
Articles could fail to meet the effectiveness review inclusion criteria but still provide useful complications data. Therefore, for the complications review, we did not require that the study be Class I-III or a Class IV study that met the 3 inclusion criteria listed in the preceding paragraph. However, we required that the article report original data on complications for Z6 months after pump implantation for Z80% of patients who received a pump during the study period. We excluded articles that reported only on a subgroup of patients with a particular type of complication. Articles that did not meet the inclusion criteria for the complications review were read to identify (but not estimate rates of) unusual serious complications that would be unlikely to occur in the small studies included in the complications review.
Two authors (J.A.T., J.M.S.) used a structured form to screen each article for these inclusion and exclusion criteria. Discrepancies were resolved by discussion. The articles that met the inclusion criteria for the effectiveness or complications review were examined closely to ensure that 2 or more articles did not report data from the same patients.
Review of Included Articles
Two authors (J.A.T., J.M.S.) independently read each article that met the inclusion criteria for the effectiveness or the complications review and recorded information using a structured abstraction form. Discrepancies were resolved by discussion. For both reviews, information was abstracted concerning study and sample characteristics, IDDS drugs and dosages initially and at follow-up assessments, and complications associated with the trial and with the permanent IDDS. For the effectiveness review, information was also abstracted concerning pain and functioning measures and results.
The complications portion of the abstraction form included a structured list of complications reported in articles we reviewed for the purpose of form development before screening articles and complications identified from one author's (J.D.L.) extensive clinical experience. We grouped complications into 2 major categories: (1) biologic complications, including infection, cerebrospinal fluid (CSF) leakage, pump rotation/malposition, and pharmacologic side effects; and (2) hardware complications, including catheter-related problems, mechanical pump failure or battery failure within 5 years of implant, and programming or other technical problems. We also recorded data regarding operations to revise the equipment and to remove pumps permanently. In cases involving a complication that resulted from another complication, we recorded only the initial, causal complication; for example, if a catheter kink was described as resulting from pump rotation in the pocket, we recorded only the pump rotation as a complication. We abstracted all complications reported, including those that were not listed on the abstraction form.
Analysis
Because the studies reviewed were clinically heterogeneous, were not controlled or comparison trials, and used a variety of outcome measures, our analysis was generally qualitative rather than quantitative. However, we did calculate mean pain intensity ratings (weighted by study sample size) before and after IDDS implantation and the mean rate of specific complications (weighted by sample size) across those studies that provided sufficient data. For the calculation of mean rates of complications, we included only studies in which the number of patients with the complication and the number of patients assessed for that complication could be determined. If an article did not mention the complication, we did not include that article in the calculation of the mean rate across studies.
RESULTS
Search Results
Among all the articles identified through the searches described above, after eliminating articles that did not meet the 4 basic inclusion criteria (eg, articles in languages other than English; studies of cancer pain or of nonprogrammable pumps), 78 seemed to be possibly appropriate for the effectiveness or complications review and were therefore reviewed for all inclusion and exclusion criteria. Among these, 52 articles were excluded from both the effectiveness and complications review based on the same criterion: 26 because they were case reports ; 13 because they did not report data separately for patients with programmable IDDS, 39-51 9 because >10% of the sample had spasticity or a specific disease [52] [53] [54] [55] [56] [57] [58] [59] [60] ; and 4 because they focused only on patients who had not responded to their first IDDS drug. [61] [62] [63] [64] (Where there was more than 1 reason for exclusion, we noted only the first reason identified.) Twenty other articles were excluded from the effectiveness review; 14 because they did not meet the study methodology criteria 65-78 and 6 because they did not report pre-IDDS data on pain or functioning. [79] [80] [81] [82] [83] [84] The remaining 6 articles 7,85-89 were included in the effectiveness review.
In addition to the 52 articles excluded from the effectiveness and complications reviews for the same reason, 16 articles were excluded from the complications review because they did not report original data on complications for Z6 months after pump implantation for Z80% of study participants who received a pump. [65] [66] [67] [68] [70] [71] [72] [73] [77] [78] [79] [80] [81] [82] [83] [84] This left 10 articles 7,69,74-76,85-89 that met the inclusion criteria for the complications review.
The articles that met the inclusion criteria for either review were examined for redundancy. One investigator was an author on 2 articles 75, 76 included in the complications review, but the articles reported results from different studies. Two investigators were authors on 2 articles included in the effectiveness and complications reviews, 88, 89 but the studies were of different patients enrolled during different time periods. Two patients may have been enrolled in 2 studies included in both the effectiveness and complications reviews 85, 89 (Valerie Anderson, personal communication), but the other patients differed between studies and the articles reported different outcome measures. Finally, another 2 articles 7,86 that were included in both the effectiveness and the complications reviews had the same first author, but reported on independent patient samples (Krishna Kumar, personal communication). Table 1 summarizes features of the 6 studies that met the inclusion criteria for the effectiveness and complications reviews and the 4 additional studies that met the criteria only for the complications review. Among the 10 articles, only 5 reported dates of study participant enrollment or pump implantation: the start date ranged from July 1989 to February 1999 and the end date ranged from September 1992 to August 2000. The number of patients who received permanent IDDS ranged from 11 to 136 (total N = 342) and follow-up time ranged from 6 to 60 months across the 10 studies. Four articles acknowledged funding from Medtronic, Inc; none acknowledged government funding; and 6 did not mention the source of financial support.
Study Characteristics
All 6 articles included in the effectiveness review were observational (Class IV); there were no RCTs of the effectiveness of programmable IDDS. Four [86] [87] [88] [89] were case series or cohort studies without comparison groups. One of these studies 89 involved a randomized comparison of the IDDS trial procedures, but not of the permanent IDDS. In one study, 85 data were collected prospectively from different centers and some follow-up information was provided for 14 of 30 (47%) patients who underwent a trial but did not receive a permanent IDDS. However, the article did not include statistical comparisons of patients who did versus did not receive permanent IDDS. In the sixth study, 7 88 patients who had failed to achieve satisfactory pain relief with spinal cord stimulation (SCS) and thus had their stimulators removed were described (page 804) as having been ''randomly divided into 2 groups of 44 patients each and were matched for patient age and sex and the number of [spine] operations undergoney Each patient was followed for a period of five years.'' Patients in 1 group received an IDDS trial; the other group was not offered IDDS and continued to receive ''conventional pain therapy.'' Results were reported for patients in the first group who had a successful trial and subsequent permanent IDDS (those who failed the IDDS trial were not followed) and for patients in the second group; however, the 2 groups were not compared statistically at baseline or at follow-up. Among the 6 studies in the effectiveness review, 2 were exclusively of patients with FBSS and the other 4 each included a number of patients with FBSS along with patients with other pain diagnoses. The mean percent of patients trialed who were implanted with a permanent pump was 72% (range, 52% to 87%) across the 6 studies. Table 2 shows information relating to the intrathecal drugs and dosages used in each study initially and at the last follow-up. No studies of ziconotide met the inclusion criteria for either the effectiveness or the complications review. Follow-up doses varied considerably within studies. Increases over time in morphine-equivalent doses were observed in each of the 7 articles that reported morphine-equivalent doses ''initially'' and at follow-up. However, in 4 of these articles, ''initial'' was undefined; in 1, it was the dose during the trial; in 1, it was the dose 1 month after the trial, and in 1 it was the dose 3 months after the trial. Excluding the study that reported the trial dose as the initial dose, the change in mean dose over time ranged across studies from a 2.6-fold increase (from 1 mo after implantation to a follow-up ranging 10 to 56 mo) to a 7.4-fold increase (from the initial dose, with initial undefined, to a 24-mo follow-up).
Drugs and Dosages
The time course of intrathecal morphine-equivalent dose increases also varied across studies. In one study, 88 the average dose increased relatively rapidly during the first 3 to 6 months of IDDS therapy, then remained fairly constant over the next 12 months, then increased again from 18 to 24 months. In another study, 75 the average dose increased gradually over the first 15 months, followed by smaller increases from 15 to 21 months. Yet another article 87 reported stable average doses from 1 to 3 months, then gradually increasing doses from 3 to 24 months.
In most studies, some patients were given adjuvant intrathecal drugs in addition to morphine or were changed from morphine to another drug to manage either inadequate pain relief or intolerable side effects. For example, 1 article 7 reported that because pain relief with morphine decreased despite dose escalation, 4 of 23 (17%) patients were changed to other drugs within the first 6 months. In another study, 88 among 23 patients followed at 24 months, 2 (9%) had been switched to hydromorphone because of poor pain control with morphine, 2 (9%) had been switched to hydromorphone due to side effects of morphine, and 5 (22%) were on an opioid plus bupivacaine ( Table 2 ).
The literature also indicates that some patients with permanent IDDS also use systemic (eg, oral) opioid medication ( Table 2) . One article 85 reported that such supplementation increased over time. Relative to baseline, at 6 months, 65% of the patients had decreased or discontinued systemic opioids, but at 12 months, only 42.5% had.
Effects on Pain
All 6 studies included in the effectiveness review found improvement in pain on average among the patients who received a permanent IDDS and provided follow-up data ( Table 3 ). Across the articles that provided mean pain intensity scores on visual analog or numerical rating scales, mean (weighted by sample size) ratings on 0 to 100 scales were 82 pre-IDDS (3 studies), 45 at 6 months (3 studies), and 44 at 12 months (2 studies). However, the attrition rate was high in the 2 articles that reported exact mean pain intensity ratings at a uniform follow-up time longer than 6 months.
Data were conflicting as to whether effects of IDDS on pain change over time. One article 88 reported that patients' pain intensity ratings increased at 24 months (Table 3) ; however, changes in group averages are difficult to interpret because of patient attrition. One other study 86 also found that pain ratings increased at longer-term (after 18 mo) follow-up. In both studies, average pain scores at the last follow-up were still substantially lower than pre-IDDS (Table 3 ). In another study, pain ratings remained fairly stable from 6 to 24 months. 87 Pain ratings were also stable from 6 to 12 months in a study that did not include follow-up beyond 12 months. 85 Three articles reported follow-up ''success rates'' of IDDS in terms of the number of patients who continued to use their pump and had Z50% reduction in pain. In the first of these, 88 the success rate by this criterion at 24 months was 36% excluding patients lost to follow-up and 30% if patients lost to follow-up are considered treatment failures. In the second study, 86 the success rate by this criterion was 38% at 6 months and 44% at the last follow-up (mean = 29 ± 12 mo). In the third study, 89 the success rate at 6 months was 63% excluding patients lost to follow-up and 56% if patients lost to follow-up are considered treatment failures.
One article 85 reported outcomes for 14 of 30 (47%) patients who underwent a trial for IDDS but did not receive a permanent implant (some had a successful trial, some did not). The authors reported that back and leg pain ratings ''remained stable'' in this group through 6 and 12 months after the baseline evaluation, in contrast to the decreases in the pain ratings of the IDDS group. However, the article did not report statistical comparisons of the 2 groups at baseline or at follow-up, adjusted for baseline differences in pain and other patient characteristics.
Effects on Functioning
All 6 articles in the effectiveness review reported some improvement in patient physical functioning with IDDS; however, each suffered serious methodologic problems (Table 4 ). In the article 85 that provided outcome information for 47% of the patients who underwent a trial for IDDS but did not receive a permanent system, the authors reported that Oswestry Disability Index 90 scores remained stable in this group through 6 and 12 months after the baseline evaluation, in contrast to improvements in the Oswestry scores of the IDDS group. However, they did not report statistical comparisons.
Little information bearing on changes in patient functioning over time was reported ( Table 4 ). In one study, 88 mean scores on patient visual analog scale ratings of functional limitations decreased from baseline to 3 months, then remained fairly stable through 24 months; however, the measure was unvalidated and the attrition rate was high. In this same study, total scores on the Chronic Illness Problem Inventory, 91 a measure of various problems such as sleep, inactivity, and psychosocial functioning, were improved significantly at 3 to 12 months relative to baseline, but did not differ significantly from baseline at 18 and 24 months. As detailed in Table 4 , serious methodologic problems limited our ability to draw conclusions from the other studies concerning whether effects of IDDS on physical functioning changed over time.
Four articles provided information on work status. In the first article, 88 47% of the patients were ''disabled'' at baseline and, of those assessed at 24 months, 35% were disabled; however, only 20 of the original 30 patients 89 Scores on a measure of function improved from baseline to 6 mo Unclear whether improvement was clinically or statistically significant Deer et al 85 Oswestry scores decreased from 44.8 (n = 132) at baseline to 32.1 (n = 90) at 6 mo and 31.0 (n = 59) at 12 mo. At baseline, 30% scored in the minimal to moderate disability range, and 60% in the severe range. At 12 mo, 73% were in the minimal to moderate range and 22% were in the severe range. At 12 mo, 66% showed improvement of at least one level on the Oswestry High loss to follow-up; unknown how those not followed differed (at baseline or at follow-up) from those assessed at follow-up CIPI indicates Chronic Illness Problem Inventory. were assessed at 24 months and within-patient changes in work status were not reported. In the second study, 86 no patients were working at baseline and ''there was no significant increase in number of patients returning to employment before and after intrathecal morphine therapy'' (page 83). In the third study, 2 patients who had been working with intermittent time loss before implantation continued to work after implantation ''with increased comfort and without any disruptions'' and 2 patients unemployed before implantation were able to work part-time after implantation. 7 No patient in a comparison group of patients who received ''conventional pain treatment'' but not IDDS returned to work during the study period. The fourth article 85 reported work status only for patients who provided baseline and 6month data (105 of 136 patients implanted). Among those working, working at reduced capacity because of pain, or not working because of pain at baseline (n = 69), 62% were at the same status, 25% were at a worse status, and 13% at a better status at 6 months. Among patients assessed at 12 months (n = 47), 68% were at the same status, 11% at a worse status, and 21% at a better status.
Complications
Of the 10 articles included in the complications review, 8 did not provide any information concerning complications during the IDDS trial. One article reported only that there were no infections or meningitis during the trial. 86 In the only article that provided more complete data on trial-related complications, 89 pharmacologic side effects during the trial were common. Most were mild, but 15 of 37 (41%) patients trialed had urinary retention and 10 of these required catheterization for several days. Nine of the 37 patients (24%) had trial procedure-related complications such as difficulty accessing the intrathecal space, mild swelling and pain at the injection site, and postdural spinal headache. Table 5 summarizes the types and rates of complications with permanent IDDS. The average duration of follow-up across the 10 studies included in the complications review was 27 months; however, the range of follow-up times varied considerably within most studies. Nonpharmacologic biologic complications included wound infection (weighted mean = 12% across 3 studies), meningitis (2%, 3 studies), and pump malposition (17%, 2 studies). CSF leaks during catheter placement leading to postdural headache were not reported commonly. Among the 10 studies, 7 7,69,75,76,86,87,89 did not mention this complication, 2 85,88 mentioned it but did not provide data sufficient to calculate the rate, and 1 74 reported that no patients had it.
The most commonly reported drug side effects were nausea/vomiting (weighted mean = 33% of patients across 3 studies), [74] [75] [76] urinary retention (24%, 4 studies), 69, [74] [75] [76] and pruritus (26%, 3 studies). [74] [75] [76] Other side effects mentioned were provocation of asthma, 86 insomnia, 86 dry mouth, 86 nightmares, 86 myoclonic jerk/ spasm, 86 dizziness, 76, 86 loss of appetite, 86 diarrhea, 76 and headache. 76 Hardware complications were reported commonly. Across the 2 studies that reported information sufficient to calculate the percent of patients who had one or more catheter-related complication after permanent IDDS implantation, the weighted mean rate was 18%. On average across studies (weighted by sample size), 12% of patients with permanent IDDS had catheter migration or dislodgement, 19% had a catheter obstruction or occlusion, and 5% had mechanical failure of the pump or battery (excluding normal battery replacement). On average across studies, 27% of patients (range across the 4 studies = 13% to 39%) had one or more equipment revisions requiring another operation (mean followup = 26 mo). On average, 5% (range across 7 studies = 0% to 27%) of patients had their IDDS permanently removed by the time of follow-up (mean follow-up = 32 mo).
We were unable to evaluate whether improvements in catheters over time have resulted in lower rates of complications such as catheter kinking and breaking. Only 2 studies provided data sufficient to calculate overall catheter-related complication rate, and they were published in the same time period (2001 to 2002; Table 5 ). Only 2 studies reported data sufficient to calculate rate of catheter migration or dislodgement; although the rate was higher in the 1995 than in the 2001 study, each study was quite small and it is unknown whether the lower rate in the 2001 study was due to a difference in the catheters used. Only one other catheter complication (obstruction/ occlusion) rate could be calculated in more than one study and these studies enrolled all patients before 1996.
Two other adverse events were mentioned in one of the articles included in the complications review: among 30 patients, one showed drug-seeking behavior and one received an overdose of morphine and bupivacaine due to a programming error. 88 In the articles that did not meet the inclusion criteria for the complications review but were examined for unusual adverse events, we also found reports of drug abuse and overdose. There was one account of a patient self-draining morphine from her pump to use parenterally. 25 Several articles described opioid overdose from various causes: changes from one intrathecal opioid medication to another 37 ; programming errors 22 ; surgeon flushing the line accidentally with morphine rather than saline after placing an intrathecal catheter 26 ; and pump refill via the side port instead of the drug reservoir port, resulting in the morphine going directly into the CSF. 32 Groudine et al 26 also commented on 2 deaths reported to the device manufacturer that resulted from massive intrathecal morphine overdoses due to mistakenly injecting morphine into an access port connecting directly to the CSF.
There were a number of reports of intrathecal granulomas at the tip of the intrathecal catheter, some of which were large enough to cause spinal cord compression and neurologic dysfunction such as urinary incontinence and paraparesis or paraplegia. 14, 21, 23, 24, 31, 35, 36, 79 There were case reports of traumatic syrinx owing to penetration of the spinal cord by the intrathecal 29 There was a report of withdrawal symptoms due to catheter disconnection from the pump. 28 
Predictors of Response to IDDS
No study included in the effectiveness review systematically examined predictors of response. One article 86 reported that the patients with nociceptive pain had the best pain relief initially after permanent IDDS implantation but, at an average of 29 months after implantation (when all patients were on morphine and 2 were also on clonidine), patients with deafferentation pain had the best results, patients with neuropathic pain had the least pain reduction, and patients with mixed or nociceptive pain had a result in between. However, the size of each pain subgroup was very small and statistical analyses adjusting for other group differences that might have affected response were not reported. In another study, 85 there were no statistically significant associations between IDDS trial success and patient age, patient gender, patient's previous pain treatments, whether psychologic evaluations had been performed, clinical site, trial methods, trial duration, and medical insurance. However, among patients who were trialed with opioids alone, those with neuropathic pain had a significantly lower success rate than did those with mechanical or mixed pain (89% vs. 100%).
DISCUSSION
The strongest level of evidence for the efficacy of a pain treatment, at least one systematic review of multiple well-designed RCTs, 92 is not available for programmable IDDS for chronic noncancer pain. The next strongest level of evidence, a well-designed RCT of appropriate size, 11, 92 is also not available. Because there were no RCTs, we included observational studies in our review. Although case series are considered the weakest study design for producing evidence on a treatment's effectiveness, it may be necessary to review them when there is no stronger evidence and when clinical or funding exigencies make it unacceptable to wait for better studies. 93 These conditions are present; patients, health care providers, and payers are making decisions about this treatment option for chronic pain. Findings of significant benefits in observational studies support the need for further, more rigorous, research. Furthermore, case series can provide credible adverse event information.
In all 6 studies that met the inclusion criteria for our review of programmable IDDS effectiveness, pain improved on average among patients who received a permanent IDDS. Across articles that reported mean 0 to 100 pain intensity ratings, pain intensity decreased from a mean of 82 pre-IDDS to 45 at 6 months and 44 at 12 months. However, the number of studies was very small (3 articles reported pain intensity ratings at 6 mo and 2 at 12 mo) and the follow-up ratings may be biased by the high attrition rates. Pain intensity ratings seemed to remain fairly stable over the first year after IDDS implantation; data regarding changes after the first year were inconclusive. Success rates (proportions of patients with Z50% pain relief, with patients lost to follow-up considered failures) ranged from 38% to 56% at 6 months and from 30% to 44% at longer follow-ups. However, only 2 articles reported success rates at followups longer than 1 year and only 2 reported mean pain intensity ratings both preimplantation and at follow-ups longer than 1 year. More research, with regular follow-up over many years of all patients enrolled, is needed to draw conclusions about the long-term effects of IDDS on clinical outcomes. It should also be emphasized that the effectiveness of IDDS relative to other treatments or ''usual care,'' and the extent to which changes in pain in these studies were due to IDDS versus natural history, nonspecific (placebo) effects, and oral opioid and other treatment use, are unknown.
Similar cautions should be applied to the interpretation of the articles' reports of improvement in physical functioning among patients who received permanent IDDS. Furthermore, only 2 studies used validated measures of physical functioning and both had serious methodologic flaws. Little could be gleaned concerning changes in patient work status with IDDS. The mean intrathecal morphine-equivalent dose increased 2.6-fold to 7.4-fold over the follow-up period within studies that reported this information. Although the extent of increase is affected by the time of the initial dose reported and also the length of follow-up, these data indicate that escalating opioid doses were needed to maintain pain relief. Furthermore, some patients required adjuvant medication with morphine or a different drug to manage inadequate pain relief or intolerable side effects with morphine.
The studies reviewed yielded little information on predictors of response to IDDS, although 2 studies suggested that the neuropathic pain may be less responsive than other types of pain to opioids delivered via IDDS. This is in consistent with the impressions of many physicians who implant IDDS. 3 Further research is needed to evaluate more rigorously whether certain types of pain respond differentially to different intrathecal drugs.
Although life-threatening complications with IDDS were rare, other adverse occurrences were reported frequently. The nonpharmacologic biologic complications reported most often were pump malposition (weighted mean = 17%) and wound infection (weighted mean = 12%). Drug side effects were also common. Nausea/vomiting, urinary retention, and pruritus were reported in one-quarter to one-third of patients with permanent IDDS, on average. These rates are fairly similar to those in a previous review 9 that included different types of IDDS and drugs for both cancer and noncancer pain; those investigators found that most common drug side effects were nausea and vomiting (25%), urinary retention (19%), myoclonic activity (18%), sedation (17%), and pruritus (17%). However, we found only a 2% mean rate of sedation and little mention of myoclonic activity. Trial drug dosing as well as permanent IDDS drug and dosing affect permanent IDDS drug side effects, and should be considered when evaluating drug side effects reported with permanent IDDS.
Intrathecal opioids have been reported to cause hypogonadism, amenorrhea, decreased libido, and erectile dysfunction, and it has been recommended that patients considering IDDS be informed of this. 78, 80, 82 In our review, only 2 articles reported rates of sexual dysfunction (weighted mean rate = 25%). We recommend systematic assessment and reporting of sexual function in future studies.
Among the articles that did not meet the complications review inclusion criteria but were reviewed for unusual complications, there were a number of reports of intrathecal catheter tip granulomas that caused neurologic injury. A review of the literature and reports by Medtronic, Inc, to the US FDA as of 11/30/2000 identified 41 cases of such granulomas from 1990 to 2000 and concluded that some cases were undoubtedly missed. 94 A more recent review also concluded that intrathecal catheter-related granulomas may be underreported in the literature. 95 Catheter-related problems (eg, migration, dislodgement, kinking, obstruction, occlusion) were reported commonly. We were unable to evaluate whether improvements in catheters have resulted in decreased catheterrelated complications. On average across studies, 27% of patients (range, 13% to 39%) had equipment revision surgery and 5% (range, 0% to 27%) had their pumps removed permanently.
The average follow-up across the studies included in the complications review was only 27 months and the range of follow-ups varied considerably within most studies; longer and more complete follow-ups are needed to learn more about complications over longer periods of time. Furthermore, the mean complication rates calculated in this review, which are based on a small number of studies, may differ considerably from actual rates. Several issues made it impossible to precisely estimate true rates. First, the variable length of patient follow-up across and within studies could affect the complications and rates reported. Second, if an article did not mention a complication, we had no way of knowing whether the complication occurred but was not reported or whether it did not occur. We did not include articles that did not mention a specific complication in the calculation of mean rates across studies; this might have resulted in an estimated mean rate higher or lower than the true rate. Third, often it was unclear how complications were assessed (eg, medical records review, systematic questioning of patients, patient spontaneous complaint). Obtaining information on complications through only one source may result in underreporting. Fourth, frequently it was unclear how many patients in a study had a particular complication and how many patients were assessed for that complication; thus, we could not calculate a rate for that study. Fifth, sometimes it was unclear whether a particular complication that occurred more than once in a study occurred in different patients or occurred more than once in the same patient(s). A final consideration is that some symptoms may have been attributed erroneously to the intrathecal medication.
The rates and types of complications reported varied widely across studies, probably because of the small sample sizes and differences in patients, IDDS hardware and drugs, clinical settings, surgeon experience with IDDS, complication assessment and reporting, length of follow-up, and other factors. Large prospective studies (eg, multicenter) with systematic assessment and reporting of all adverse events associated with trial and permanent IDDS are needed to better estimate adverse event rates. There is a need for a reliable, valid method for categorizing IDDS complications in terms of type, preventability, and severity. The ability to estimate rates of rare serious complications will likely require large-scale postmarketing surveillance strategies and public access to data collected in such efforts. Table 6 lists our recommendations for future studies. Randomized trials are clearly needed. We acknowledge the difficulties of conducting an RCT of IDDS versus a sham or placebo control for chronic pain. However, randomized comparisons of IDDS with other treatments, despite challenges associated with funding and patient recruitment, are possible. The state of the literature on IDDS for chronic noncancer pain is similar to that of another chronic pain therapy requiring an operation, SCS. For both therapies, most studies are case series. 96, 97 However, there is one RCT of SCS. 98, 99 Lumbar spinal fusion, another operation performed to relieve chronic back pain, has been the patient of several RCTs involving comparisons with nonsurgical therapies. [100] [101] [102] These RCTs of other surgical therapies could be used as examples to guide the development of RCTs to evaluate IDDS.
Even in the absence of RCTs, studies could be designed that would improve upon those in the current literature. Nonrandomized comparisons of IDDS with alternative treatments or ''treatment as usual'' would provide stronger evidence than case series if study design features included: (1) patients in different treatment groups comparable on demographic and baseline pain characteristics; (2) validated measures of pain, physical functioning, and psychosocial functioning administered independently of the treating team before the IDDS trial and at regular follow-ups; and (3) appropriate statistical analyses. Administration of the same measures at the same intervals across studies would facilitate metaanalysis. Extensive efforts should be made to collect follow-up data on all patients enrolled, including those who do not receive permanent IDDS and those who have permanent IDDS removed.
This review focused only on programmable pumps because most of the IDDS pumps currently used for chronic pain are programmable. Many potentially relevant studies were excluded because they did not specify the pump type used or because they mixed data from different pump types. A comparison of fixed-rate and programmable pumps could not be conducted because differences in pump type would be confounded with other study differences that could affect complications and outcomes (eg, years of study, patient and pain characteristics). Findings from this review concerning effectiveness and complications cannot be generalized to fixed-rate pumps. Some complications and other events requiring intervention (eg, programming errors, battery failure) are unique to programmable pumps, and research is lacking on the comparative effectiveness of the two systems. Timing: before IDDS trial and at regular, planned follow-ups of at least 1 y and preferably 2 y Measures: valid, reliable measures of patient pain, physical functioning, and psychosocial functioning, with treating physician unaware of individual patient responses; systematic, regular assessment of complication types and severity using multiple sources of information (eg, systematic patient questioning, medical records review, treating physician-completed measures) Method: patient-completed outcome measures administered by someone not part of the treatment team; ideally, supplemented by objective measures (eg, of physical functioning) completed by someone not part of the treatment team Follow-up: assessment of all patients enrolled in study, regardless of IDDS status Reporting Numbers of patients who (1) were approached for study participation, (2) were ineligible for the study, (3) were eligible but declined to participate, (4) underwent IDDS trial, (5) had a successful trial, (6) had an unsuccessful trial, (7) received permanent IDDS, and (8) provided data at each follow-up Sample demographics, pain diagnoses, other relevant clinical characteristics Clinical and study-related inclusion and exclusion criteria Study enrollment dates Surgeon experience with IDDS (as this may affect outcomes and complications) Type(s) of pumps and catheters used Types of IDDS and other (eg, oral, transdermal) medications used and dosages initially and at each follow-up Separately for patients who were trialed but did not receive permanent IDDS and for those who received permanent IDDS, means and standard deviations of outcome measures before the trial and at 6, 12, and 24 mo after the trial Statistical tests used (intent-to-treat analysis in RCTs) and results Among all patients enrolled, including those who did not receive permanent IDDS, number and proportion with clinically meaningful improvement, as determined by criteria specified before beginning the study (eg, Z50% pain relief), at 6 mo, 1 y, and 2 y; and changes within patients over time in whether they meet the criterion for clinically meaningful improvement (eg, among patients with Z50% pain relief at 6 mo, how many have this level of pain relief at 1 y?)
For each adverse event mentioned in this review: (1) number and proportion of patients who had the event during the IDDS trial, and (2) number and proportion of patients who had the event during or after permanent IDDS implantation (if no patient had a specific complication, an explicit statement to that effect; if adverse events not mentioned in this review occurred, provision of information about those events). For each adverse event that occurred in the study: (1) length of time between IDDS implantation and the complication, (2) duration of the complication (if a biologic complication such as a drug side effect), and (3) rating of complication severity Source(s) of all funding for the study In conclusion, on average among patients with chronic noncancer pain who have a successful IDDS trial and go on to receive permanent IDDS, pain seems to improve, but increases in opioid dosage and changes in medication are often needed to maintain pain improvement. Long-term effects on pain remain unclear, given the paucity of data from follow-ups longer than 1 year. Furthermore, the effectiveness of IDDS in improving pain and function, as compared with a placebo, natural history, or other treatment, is unknown. Drug side effects and other complications requiring additional surgeries are common.
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